These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26354293)

  • 1. Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration.
    Takahata M; Hashino S; Nishio M; Sugita J; Shigematsu A; Onozawa M; Fujimoto K; Endo T; Kondo T; Tanaka J; Imamura M; Teshima T
    Transpl Infect Dis; 2015 Dec; 17(6):810-5. PubMed ID: 26354293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ; Al Mohareb F; Al Rabiah F; Chaudhri N; Al Sharif F; Al Zahrani H; Mohamed SY; Patel M; Rasheed W; Nurgat Z; Bakr M; Ahmed S; Zaidi S; Nasser A; Ibrahim K; Al Abdely H; Aljurf M
    Hematol Oncol Stem Cell Ther; 2010; 3(3):116-20. PubMed ID: 20890068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the patient's body weight on the efficacy and adverse events of valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell transplantation.
    Misaki Y; Kimura SI; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Yoshimura K; Gomyo A; Matsumi S; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
    Transpl Infect Dis; 2020 Jun; 22(3):e13270. PubMed ID: 32092224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.
    Ayala E; Greene J; Sandin R; Perkins J; Field T; Tate C; Fields KK; Goldstein S
    Bone Marrow Transplant; 2006 May; 37(9):851-6. PubMed ID: 16532016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
    Cintra-Cabrera M; Suárez-Benjumea A; Bernal-Blanco G; González-Roncero FM; Toapanta-Gaibor NG; Súñer-Poblet M; Pérez-Valdivia MÁ; Fernández-Cuenca F; Gentil-Govantes MÁ; Rocha-Castilla JL
    Transplant Proc; 2018 Mar; 50(2):575-577. PubMed ID: 29579856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM; Lake KD; Arenas JD; Fontana RJ
    Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
    Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
    Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
    PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?
    Kaynar L; Metan G; Gökahmetoğlu S; Kurnaz F; Mumcuoğlu H; Öztürk A; Şıvgın S; Pala C; Yıldız O; Eser B; Ünal A; Çetin M
    J Chemother; 2013 Oct; 25(5):286-91. PubMed ID: 24070136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
    Liu KY; Wang Y; Han MZ; Huang H; Chen H; Liu QF; Wang JM; Liu T; Song YP; Ma J; Wu DP; Zou P; Huang XJ
    Chin Med J (Engl); 2010 Aug; 123(16):2199-205. PubMed ID: 20819665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
    Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
    J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Bixby AL; Fitzgerald L; Park JM; Kaul D; Tischer S
    Transpl Infect Dis; 2021 Oct; 23(5):e13713. PubMed ID: 34428337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
    Serio B; Rosamilio R; Giudice V; Pepe S; Zeppa P; Esposiito S; Pezzullo L; Rocco M; Montuori N; Selleri C
    Infez Med; 2012; 20 Suppl 2():26-34. PubMed ID: 23042003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
    Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
    Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
    Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure.
    Lefeuvre S; Chevalier P; Charpentier C; Zekkour R; Havard L; Benammar M; Amrein C; Boussaud V; Lillo-Le Louët A; Guillemain R; Billaud EM
    Transpl Infect Dis; 2010 Jun; 12(3):213-9. PubMed ID: 20102551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.